Erasca, Inc.
ERAS- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001761918
Insider trades, last 90 days
None
- No open-market purchases or sales were filed in the last 90 days.
13F holders, Q2 2026
256
- +31 vs. Q1 2026
- Total value $5.14B
Superinvestors holding ERAS
0
- None of the superinvestors held ERAS at the end of Q2 2026.
Price chart
Latest insider trades
View all: Latest insider tradesOpen-market purchases and sales by ERAS insiders, newest first.
| Filed (ET) | Trade date | Insider | Transaction | Shares | Avg price | Value | Shares after | Holding change | Filing |
|---|---|---|---|---|---|---|---|---|---|
| Apr 3, 2026 | Apr 1, 2026 | Garner EbunChief Legal Officer | SSaleCommon Stock | −80K | $16.40 | −$1.31M | 25.08K | −76.1% | SEC10b5-1 |
| Mar 6, 2026 | Mar 4, 2026 | Morris ShannonChief Medical Officer | SSaleCommon Stock | −20K | $15.04 | −$300.8K | 0 | −100.0% | SEC10b5-1 |
| Jan 8, 2026 | Jan 7, 2026 | Garner EbunGeneral Counsel & Corp. Sec. | SSaleCommon Stock | −120K | $5.59 | −$670.8K | 25.08K | −82.7% | SEC10b5-1 |
| May 22, 2024 | May 21, 2024 | Casdin Alexander W.Director | PPurchaseCommon Stock | +80K | $2.27 | +$181.6K | 573.97K | +16.2% | SEC |
| Dec 8, 2023 | Dec 6, 2023 | Start Valerie Denise HardingDirector | PPurchaseCommon Stock | +10K | $1.85 | +$18.5K | 20K | +100.0% | SEC |
Top 5 13F holders, Q2 2026
View all: Top 5 13F holders, Q2 2026The largest institutional positions in ERAS at the end of Q2 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 24,975,188 | $457.55M | 9.96% | +300,000+1.2% | Added |
| T. Rowe Price Investment Management, Inc. | 21,185,839 | $388.13M | 0.25% | −73,807−0.3% | Reduced |
| BlackRock, Inc. | 21,154,146 | $387.54M | 0.01% | +1,002,740+5.0% | Added |
| RTW INVESTMENTS, LP | 17,946,754 | $328.78M | 2.81% | +1,789,579+11.1% | Added |
| VR Adviser, LLC | 17,891,812 | $327.78M | 9.94% | +1,509,000+9.2% | Added |